X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
REC610 (recombinant shingles vaccine) is a recombinant herpes zoster vaccine which is under phase 1 clinical trials. It is a recombinant protein technology which can induce high levels of gE-specific CD4+ T cell responses and IgG antibody.
Lead Product(s): Recombinant Shingles Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: REC610
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2023
Details:
REC610 is a recombinant herpes zoster vaccine using recombinant protein technology similar to Shingrix® and showing immunogenicity not inferior to Shingrix® in animal studies.
Lead Product(s): Recombinant Shingles Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: REC610
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2023
Details:
REC610 has favorable immunogenicity and can induce high levels of gE-specific CD4+ T cell responses and IgG antibody, and its immune response is non-inferior to the controlled vaccine Shingrix.
Lead Product(s): REC610
Therapeutic Area: Infections and Infectious Diseases Product Name: REC610
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
Preclinical studies have shown that REC610 has favorable immunogenicity and can induce high levels of gE-specific CD4+T cell responses and IgG antibody, and its immune response is non-inferior to the controlled vaccine Shingrix®.
Lead Product(s): Adjuvanted Recombinant Shingles Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: REC610
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
The REC604a (adjuvanted recombinant quadrivalent HPV vaccine) is equipped with the novel adjuvanted BFA04 independently developed by the Company, which aims to reduce the dose of vaccination by enhancing the immunogenicity and cross-protection effects.
Lead Product(s): Adjuvanted Recombinant Quadrivalent HPV Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: REC604a
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
ReCOV is a recombinant COVID-19 vaccine developed by the company using new adjuvants, protein engineering platforms and other technology platforms. Its adjuvant uses the self-developed new adjuvant BFA03.
Lead Product(s): ReCOV
Therapeutic Area: Infections and Infectious Diseases Product Name: ReCOV
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2022
Details:
Completed Phase I clinical data of REC603 (Recombinant Nine-valent HPV Vaccine) shows that safe and well tolerated with favorable immunogenicity profile. REC603 adopts H. polymorpha expression system to achieve high-yield and stable expression of HPV virus-like particles.
Lead Product(s): Recombinant Nine-valent HPV Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: REC603
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
ReCOV is a recombinant COVID-19 vaccine being developed by the Company with its technology platforms including the novel adjuvant and protein engineering platforms, and the adjuvant used therein is the Company's self-developed novel adjuvant BFA03.
Lead Product(s): ReCOV
Therapeutic Area: Infections and Infectious Diseases Product Name: ReCOV
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
ReCOV (Recombinant Protein COVID-19 Vaccine), (CHO Cell) is a combination of new adjuvants, protein engineering and other technology platform to thoroughly optimize the vaccine.
Lead Product(s): Recombinant Protein COVID-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: ReCOV
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Recbio, together with Jiangsu Provincial Center for Disease Control and Prevention ("Jiangsu CDC") and Taizhou Medical New & High-tech Industrial Development Zone, jointly developed a recombinant two-component COVID-19 vaccine(ReCOV).
Lead Product(s): ReCOV
Therapeutic Area: Infections and Infectious Diseases Product Name: ReCOV
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
